4/25
08:56 am
autl
Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year [Yahoo! Finance]
Low
Report
Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year [Yahoo! Finance]
4/24
10:15 am
autl
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO [Yahoo! Finance]
Medium
Report
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO [Yahoo! Finance]
4/24
10:00 am
autl
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Medium
Report
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
4/23
07:00 am
autl
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Low
Report
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
4/15
05:31 pm
autl
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Low
Report
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
4/15
05:31 pm
autl
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Low
Report
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
4/12
08:01 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Low
Report
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
4/9
02:10 pm
autl
Autolus Therapeutics plc (NASDAQ: AUTL) had its price target raised by analysts at Truist Financial Co. from $10.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Autolus Therapeutics plc (NASDAQ: AUTL) had its price target raised by analysts at Truist Financial Co. from $10.00 to $11.00. They now have a "buy" rating on the stock.
4/2
07:23 am
autl
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-AL
Low
Report
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-AL
4/2
07:00 am
autl
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-AL
Low
Report
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-AL
4/1
07:06 am
autl
Autolus Therapeutics Announces Changes to its Board of Directors [Yahoo! Finance]
High
Report
Autolus Therapeutics Announces Changes to its Board of Directors [Yahoo! Finance]
4/1
07:00 am
autl
Autolus Therapeutics Announces Changes to its Board of Directors
High
Report
Autolus Therapeutics Announces Changes to its Board of Directors
3/25
08:20 am
autl
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee [Yahoo! Finance]
Low
Report
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee [Yahoo! Finance]
3/18
03:05 pm
autl
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Low
Report
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
3/18
02:50 pm
autl
Autolus Therapeutics plc (NASDAQ: AUTL) had its price target raised by analysts at Truist Financial Co. from $9.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
Autolus Therapeutics plc (NASDAQ: AUTL) had its price target raised by analysts at Truist Financial Co. from $9.00 to $10.00. They now have a "buy" rating on the stock.
3/17
09:34 am
autl
Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/14
07:18 am
autl
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]
Medium
Report
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]
3/14
07:00 am
autl
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Medium
Report
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
3/12
07:17 am
autl
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site [Yahoo! Finance]
Low
Report
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site [Yahoo! Finance]
3/12
07:00 am
autl
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
Low
Report
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
3/11
07:35 am
autl
Autolus Therapeutics announces publication in Blood Cancer Journal [Yahoo! Finance]
Medium
Report
Autolus Therapeutics announces publication in Blood Cancer Journal [Yahoo! Finance]
3/11
07:00 am
autl
Autolus Therapeutics announces publication in Blood Cancer Journal
Medium
Report
Autolus Therapeutics announces publication in Blood Cancer Journal
2/29
07:00 am
autl
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
Low
Report
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
2/22
07:06 am
autl
Autolus Therapeutics announces publication in Nature Communications [Yahoo! Finance]
Low
Report
Autolus Therapeutics announces publication in Nature Communications [Yahoo! Finance]
2/22
07:00 am
autl
Autolus Therapeutics announces publication in Nature Communications
Low
Report
Autolus Therapeutics announces publication in Nature Communications